The nuclear receptor superfamily is comprised of transcription factors that positively and negatively regulate gene expression in response to the binding of a diverse array of lipid-derived hormones and metabolites. Intense efforts are currently being directed at defining the biological roles and mechanisms of action Liver X receptors (LXRs) and Peroxisome Proliferator-Activated Receptors (PPARs). LXRs have been found to play essential roles in the regulation of whole body cholesterol absorption and excretion, in the efflux of cholesterol from peripheral cells, and in the biosynthesis and metabolism of very low density lipoproteins. PPARs have been found to regulate diverse aspects of lipid metabolism, including fatty acid oxidation, fat cell development, lipoprotein metabolism and glucose homeostasis. Intervention studies indicate that activation of PPARα, PPARγ and LXRs by specific synthetic ligands can inhibit the development of atherosclerosis in animal models. Here we review recent studies that provide new insights into the mechanisms by which these subclasses of nuclear receptors act to systemically influence lipid and glucose metabolism and regulate gene expression within the artery wall.
the possibility that LXR agonists may be of therapeutic utility in humans if undesirable effects on circulating triglyceride levels can be reduced or eliminated through development of selective modulators (36) .
In addition to regulating cholesterol homeostasis, recent studies suggest that LXRs may also antagonize inflammatory responses. Synthetic LXR agonists can inhibit induction of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), macrophage chemotactic protein-1 (MCP-1) and Gelatinase B by LPS or other proinflammatory cytokines (28, 56). These findings suggest previously unrecognized connections between cholesterol metabolism and inflammation.
Peroxisome Proliferator-activated Receptors
PPARa (NR1C1), PPARβ/δ (NR1C2, hereafter referred to as PPARδ), and PPARγ (NR1C3) comprise the PPAR subfamily of nuclear receptors. Although there is overlap in natural ligands that are capable of activating the three PPARs, each receptor subtype exhibits distinct patterns of expression and overlapping but distinct biological activities (57, 58).
PPARα, the first PPAR to be identified, was named based on its ability to be activated by substances that drive peroxisome proliferation in rodents (59). The cloning of PPARα cDNAs also led to the recognition of PPARα as the molecular target of fibrates, such as gemfibrizol, that are used in the treatment of hypertriglyceridemia (60, 61). Many lines of evidence indicate that PPARα regulates lipid homeostasis in part by stimulating peroxisomal β oxidation of fatty acids.
In the liver, activation of PPARα leads to the upregulation of fatty acid transport protein and long-chain acyl-Coenzyme A synthetase genes (61, 62). By increasing β oxidation, PPARα not only stimulates energy production but also shortens long chain fatty acids, thus preventing lipid accumulation and toxicity. Mitochondrial HMG-CoA synthase is also a target of PPARα and plays a role in the formation of ketone bodies (63). In addition to stimulating β oxidation, activation of PPARα has been shown to increase apolipoprotein AI and AII and decrease apolipoprotein CIII, an inhibitor of lipoprotein lipase (LPL) (64, 65). These effects would tend to increase HDL levels and decrease triglyceride levels and are thought to contribute to beneficial effects of fibrates on lipoprotein levels in hypertriglyceridemic individuals.
PPARα agonists have also been shown to regulate cholesterol homeostasis in cultured macrophages. Activation of PPARα can lead to induction of the expression of LXRα, which can then stimulate ABCA1 expression and promote efflux of cholesterol to apoAI (66) . It has also been demonstrated that PPARa can inhibit esterification of free cholsterol by ACAT-1 and increase the efflux of free cholesterol by increasing the expression of scavenger receptor B-1 (SRB-1) (67, 68) .
In addition to effects on cellular and circulating lipid levels, activation of PPARα has also been suggested to exert anti-diabetic effects by increasing insulin sensitivity. In PPARα-null mice, there is no gross alteration of insulin sensitivity (69) . However, in Zucker obese fa/fa rats and lipoatrophic mice (AZIP/F-1), activation of PPARα led to a significant improvement in insulin sensitivity (70, 71) .
Studies performed in cultured cells suggest that PPARα regulates the expression of genes that control inflammatory responses in endothelial cells, smooth muscle cells and macrophages.
PPARα has been shown to inhibit transcriptional responses to inflammatory stimuli by interfering with the activation of NF-kB, leading to the reduction of vascular cell adhesion molecule 1 (VCAM-1) in endothelial cells (72) . In vascular smooth muscle cells (VSMCs)
PPARα agonists inhibited interleukin (IL-1)-induced production of IL-6 and and COX-2 expression (73) . PPARα agonists also reduced the expression of tissue factor and matrix metalloproteinase in monocyte and macrophages, thereby decreasing thrombogenicity and plaque instability (74) (75) (76) . On the other hand, some studies have suggested potential proatherogenic consequences of PPARα activation, such as the ability of PPARα agonists to stimulate the production of MCP-1 in endothelial cells (77) , which would be expected to enhance recruitment of monocytes into lesions.
Identification of potential ligands for PPARs has primarily relied on screening candidate molecules. This approach has led to the identification of numerous natural compounds that can bind to PPARα and stimulate its transcriptional activities in cells, including polyunsaturated fatty acids such as linoleic acid, dodecahexanoic acid (DHA) and eicosapentanoic acid (EPA) (15, 78) . Because these substances bind to PPARα with relatively low affinity, it has been difficult to clearly establish their importance in vivo. An alternative strategy has been to evaluate enzymatic pathways that could potentially be involved in the local generation of ligands. In concert, the effects of PPARα agonists on lipid and carbohydrate metabolism would be expect to result in protection against development of atherosclerosis. Consistent with this, a clinical trial examining effects of the PPARα agonist gemfibrizol in men with a history of coronary heart disease and low HDL levels demonstrated a significant reduction in incidence of fatal and non fatal myocardial infarction (80) . These effects could only be partially explained by increased levels of HDL (81) , and are consistent with actions in peripheral tissues, including macrophages. However, studies of the influence of PPARα on the development of atherosclerosis in animal models have yielded conflicting results. Surprisingly, PPARα -/-/apoEdeficient mice exhibited less atherosclerosis than control apoE-deficient mice, suggesting an atherogenic role of PPARα (82) . PPARα -/-mice were found to be less insulin resistant and to have lower blood pressure compared to wild type controls (82) , potentially at least partially explaining the unexpected outcome. In another study of apoE-deficient mice, treatment with ciprofibrate worsened diet-induced hyperlipidemia and increased atherosclerosis (83) . In these studies, ciprofibrate treatment was associated with an increase in apo B48-containing lipoproteins, suggesting an effect of PPARα on editing of the apo B messenger RNA. Other studies have found that PPARα agonists are anti-atherogenic. In one study, fenofibrate had minimal anti-atherogenic effects in apoE-deficient mice (84, 85) , but exerted a more pronounced effect in apoE-deficient mice carrying a fenofibrate-inducible human apoAI transgene.
Studies in our laboratories recently demonstrated that activation of PPARα by a highly specific and potent agonist (GW7647), inhibited atherosclerosis by nearly 50% throughout the aortas of hyperlipidemic LDLR -/-mice (86) . In these studies, activation of PPARα with GW7647did not significantly alter diet-induced hyperlipidemia. However, improvement of insulin sensitivity was observed, which was associated with less weight gain in treated animals compared to control mice. Although treatment of mice with this PPARα agonist induced expression of LXRα in the arterial walls of hypercholesterolemic mice exhibiting extensive lesion formation, expression of ABCA1 did not change, consistent with previous studies using fenofibrate (85) . In concert with its effects on the development on atherosclerosis, GW7647 The sensitivity of LXR-deficient macrophages to apoptosis/necrosis following treatment with PPARα agonists raises the possibility that LXRs mediate a protective effect in wild-type macrophages. Two significant differences may explain the apparent discrepancies observed regarding the influence of PPARα agonists on the development of atherosclerosis in mice. First, initial studies were performed on a background of apoE deficiency, whereas our recent studies used LDLR-deficient mice. Apolipoprotein E is present in all lipoproteins except LDL and plays a role in the clearance of remnants and VLDL by the liver (reviewed in (88) ). Apolipoprotein E is also a LXR target gene in macrophages and can potentially serve as an acceptor for cholesterol efflux. Expression of apoE may be required for inhibition of foam cell formation by PPARα agonists. A second significant difference concerns the specific PPARα agonists that were tested for effects on atherosclerosis. Fibrates such as fenofibrate and gemfibrizol are relatively low affinity ligands for PPARα, with binding constants in the micromolar range. When used in vivo, it may be difficult to achieve effective concentrations of these drugs in peripheral tissues in mouse models. In contrast, GW7647 binds to PPARα at low nanomolar concentrations and is likely to effectively activate PPARα throughout the body (reviewed in (89)). To distinguish between these two possibilities, it will be necessary to perform intervention studies of A role for PPARγ in regulation of inflammation and immunity was initially suggested by the findings that it is expressed in macrophages and inhibits the expression of a number of proinflammatory genes, including TNFα, IL-1β, iNOS and gelatinase B (27, 115) . A large number of inflammatory responses have been shown to be subject to negative regulation by PPARγ agonists (reviewed in (112, 116) ). Initial studies of PPARγ-deficient macrophages raised questions regarding whether PPARγ agonists exerted effects on inflammatory response genes through PPARγ-dependent or PPARγ-independent mechanisms (117) . Further investigation established that both types of mechanisms contribute to these actions. For example, the PPARγ agonist 15-deoxy Δ 12,14 prostaglandin J 2 was shown to inhibit NF-κB signaling in a PPARγ-independent manner by covalently modifying IκB-kinase and NF-κB subunits (118, 119) . High concentrations of synthetic PPARγ agonists can also exert anti-inflammatory effects by binding to PPARδ (120) . When used at receptor-specific concentrations, PPARγ ligands inhibited transcriptional responses of primary macrophages to bacterial lipopolysaccharide in a PPARγ-dependent manner (120).
Recent gene expression profiling studies suggest that anti-inflammatory actions of PPARγ in macrophages may be relevant to obesity-induced insulin resistance. Through a comparison of gene expression profiles of insulin-sensitive adipose tissue derived from lean animals and insulin-resistant adipose tissue derived from obese animals, the unexpected observation was made that macrophages accumulate in adipose tissue in the setting of obesity (121, 122) . Adipose tissue macrophages were found to be a major source of inflammatory mediators that are linked to insulin resistance and are subject to counterregulation by PPARγ agonists.
In vitro studies of effects of PPARγ agonists on cholesterol homeostasis in macrophages suggested both atherogenic and antiatherogenic influences. PPARγ was found to stimulate transcription of the CD36 gene (90, 123), which is a macrophage scavenger receptor that contributes to macrophage foam cell formation and development of atherosclerosis in mice (124) . In conjunction with the finding that PPARγ can be activated by 9-and 13-HODE present in oxLDL, a 'PPARγ cycle' was proposed in which oxLDL lipids would induce the activity of PPARγ, leading to increased expression of CD36, which in turn would increase the uptake of oxLDL (90, 123). This cycle would potentially promote foam cell formation and atherosclerosis.
However, a recent finding suggests that PPARγ may actually decrease expression of CD36 protein in the context of the metabolic syndrome, and thereby reduce uptake of modified forms of LDL. Macrophages isolated from ob/ob mice exhibit impaired insulin signaling and increased expression of CD36. Treatment of peritoneal macrophages isolated from these mice with rosiglitazone had no effect on CD36 mRNA levels but reduced protein expression at the cell surface (125) . This would suggest a post-translational effect of rosiglitazone on CD36 via the insulin-signaling pathway. With respect to cholesterol efflux pathways, PPARα and PPARg were shown to induce expression of LXRα and thereby stimulate ABCA1-dependent cholesterol efflux to apoAI (66, 126) (Figure 2) , analogous to the PPARα/LXRα/ABCA1 pathway described above. The cytochrome p450 enzyme, Cyp27, which is the enzyme that catalyzes production of the weak LXR agonist 27OH-cholesterol, has recently been demonstrated to be activated by The finding that PPARα and PPARγ agonists inhibit foam cell formation raises the possibility that combined therapy or use of PPARα/γ co-agonists could have additive or synergistic protective effects in the arterial wall in addition to beneficial effects on lipid and glucose metabolism. Recent animal studies using co-agonists demonstrated combined improvements in insulin sensitivity, as well as fatty acid, glucose and lipoprotein metabolism (136, 137) . The PPARα/γ co-agonist, GW2331 decreased atherosclerosis by 32% in apoEdeficient mice (84) . Another PPARα/γ co-agonist resulted in a 2.5-fold reduction in lesion area in hypercholesterolemic apoE -/-mice and was correlated with inhibition of interferon γ and beta 2 integrin CD11a gene expression (138) .
PPARδ
PPARδ was the last of the PPARs to be identified (139) . Gene deletion studies suggest important roles of PPARδ in skin biology, lipid metabolism, and energy homeostasis (140) (141) (142) (143) . 
